Improved Adeno-Associated Virus Vector Production with Transfection of a Single Helper Adenovirus Gene, E4orf6

Molecular Therapy

Volumn 1, Issue 1, 2000, Pages 88-95

  Allen, James M ^a   Halbert, Christine L ^a   Miller, A Dusty ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Mouse; lung; transduction; AAV

Indexed keywords

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL; ARTICLE; C57BL MOUSE; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC PROCEDURES; GENETIC TRANSFECTION; GENETICS; HELPER VIRUS; HUMAN; LUNG; METABOLISM; MOUSE; PLASMID; VIRUS GENE;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; GENE EXPRESSION; GENE THERAPY; GENES, VIRAL; GENETIC TECHNIQUES; GENETIC VECTORS; HELPER VIRUSES; HUMANS; LUNG; MICE; MICE, INBRED C57BL; PLASMIDS; TRANSFECTION;

EID: 0033642972     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.1999.0010     Document Type: Article

References (71)

1. Alexander I. E., Russell D. W., Miller A. D. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J. Virol. 68:1994;8282-8287.
2. Allen J. M., Debelak D. J., Reynolds T. C., Miller A. D. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J. Virol. 71:1997;6816-6822.
3. Beaton A., Palumbo P., Berns K. I. Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep proteins. J. Virol. 63:1989;4450-4454.
4. Boivin D., Morrison M. R., Marcellus R. C., Querido E., Branton P. E. Analysis of synthesis, stability, phosphorylation, and interacting polypeptides of the 34-kilodalton product of open reading frame 6 of the early region 4 protein of human adenovirus type 5. J. Virol. 73:1999;1245-1253.
5. Chang L.-S., Shi Y., Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J. Virol. 63:1989;3479-3488.
6. Chang L.-S., Shenk T. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J. Virol. 64:1990;2103-2109.
7. Clark K. R., Voulgaropoulou F., Fraley D. M., Johnson P. R. Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6:1995;1329-1341.
8. Clark K. R., Sferra T. J., Johnson P. R. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum. Gene Ther. 8:1997;659-669.
9. Clark K. R., Liu X., McGrath J. P., Johnson P. R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther. 10:1999;1031-1039.
10. Ferrari F. K., Samulski T., Shenk T., Samulski R. J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:1996;3227-3234.
11. Fisher K. J., Gao G.-P., Weitzman M. D., DeMatteo R., Burda J. F., Wilson J. M. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70:1996;520-532.
12. Fisher K. J., Jooss K., Alston J., Yang Y., Haecker S. E., High K., Pathak R., Raper S. E., Wilson J. M. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med. 3:1997;306-312.
13. Flotte T. R., Afione S. A., Conrad C., McGrath S. A., Solow R., Oka H., Zeitlin P. L., Guggino W. B., Carter B. J. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. USA. 90:1993;10613-10617.
14. Flotte T. R., Barraza-Ortiz X., Solow R., Afione S. A., Carter B. J., Guggino W. B. An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther. 2:1995;29-37.
15. Gao G.-P., Qu G., Faust L. Z., Engdahl R. K., Xiao W., Hughes J. V., Zoltick P. W., Wilson J. M. High-titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum. Gene Ther. 9:1998;2353-2362.
16. Graham F. L., Smiley J., Russell W. C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Virol. 36:1977;59-74.
17. Grimm D., Kern A., Rittner K., Kleinschmidt J. A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9:1998;2745-2760.
18. Halbert C. L., Alexander I. E., Wolgamot G. M., Miller A. D. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. J. Virol. 69:1995;1473-1479.
19. Halbert C. L., Standaert T. A., Wilson C. B., Miller A. D. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during initial exposure. J. Virol. 72:1998;9795-9805.
20. Herzog R. W., Hagstrom J. N., Kung S.-H., Tai S. J., Wilson J. M., Fisher K. J., High K. A. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA. 94:1997;5804-5809.
21. Herzog R. W., Wang E. Y., Couto L. B., Hagstrom J. N., Elwell D., Fields P. A., Burton M., Bellinger D. A., Read M. S., Brinkhous K. M., Podsakoff G. M., Nichols T. C., Kurtzman G. J., High K. A. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med. 5:1999;56-63.
22. Horer M., Weger S., Butz K., Hoppe-Seyler F., Geisen C., Kleinschmidt J. A. Mutational analysis of adeno-associated virus rep protein-mediated inhibition of heterologous and homologous promoters. J. Virol. 69:1995;5485-5496.
23. Inoue N., Russell D. W. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J. Virol. 72:1998;7024-7031.
24. Janik J. E., Huston M. M., Cho K., Rose J. A. Efficient synthesis of adeno-associated virus structural proteins requires both adenovirus DNA binding protein and VA I RNA. Virology. 168:1989;320-329.
25. Jay F. T., Laughlin C. A., Carter B. J. Eukaryotic translational control: Adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein. Proc. Natl. Acad. Sci. USA. 78:1981;2927-2931.
26. Kessler P. D., Podsakoff G. M., Chen X., McQuiston S. A., Colosi P. C., Matelis L. A., Kurtzman G. J., Byrne B. J. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA. 93:1996;14082-14087.
27. Koeberl D. D., Alexander I. E., Halbert C. L., Russell D. W., Miller A. D. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA. 94:1997;1426-1431.
28. Koeberl D. D., Bonham L., Halbert C. L., Allen J. M., Birkebak T., Miller A. D. Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors. Hum. Gene Ther. 10:1999;2133-2140.
29. 5 rep binding site and the consensus ATP-binding motif of the AAV rep68 protein. J. Virol. 69:1995;6787-6796.
30. Laughlin C. A., Cardellichio C. B., Coon H. C. Latent infection of KB cells with adeno-associated virus Type 2. J. Virol. 60:1986;515-524.
31. Leppard K. N. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infection. J. Gen. Virol. 78:1997;2131-2138.
32. Leppard K. N. Regulated RNA processing and RNA transport during adenovirus infection. Semin. Virol. 8:1998;301-307.
33. Lewis B. A., Tullis G., Seto E., Horikoshi N., Weinmann R., Shenk T. Adenovirus E1A proteins interact with the cellular YY1 transcription factor. J. Virol. 69:1995;1628-1636.
34. Li J., Samulski R. J., Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 71:1997;5236-5243.
35. Mah C., Qing K., Khuntirat B., Ponnazhagan S., Wang X.-S., Kube D. M., Yoder M. C., Srivastava A. Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J. Virol. 72:1998;9835-9843.
36. Matsushita T., Elliger S., Elliger C., Podsakoff G., Villarreal L., Kurtzman G. J., Iwaki Y., Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5:1998;938-945.
37. McCarty D. M., Christensen M., Muzyczka N. Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by rep protein. J. Virol. 65:1991;2936-2945.
38. Muzcyzka N. Use of adeno-associated virus as a general transduction vector in mammalian cells. Curr. Top. Microbiol. Immunol. 158:1992;97-129.
39. Ni T.-H., McDonald W. F., Zolotukhin I., Melendy T., Waga S., Stillman B., Muzyczka N. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J. Virol. 72:1998;2777-2787.
40. Nordqvist K., Ohman K., Akusjarvi G. Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs. Mol. Cell. Biol. 14:1994;437-445.
41. Qing K., Wang X.-S., Kube D. M., Ponnazhagan S., Bajpai A., Srivastava A. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc. Natl. Acad. Sci. USA. 94:1997;10879-10884.
42. Qing K., Khuntirat B., Mah C., Kube D. M., Wang X.-S., Ponnazhagan S., Zhou S., Dwarki V. J., Yoder M. C., Srivastava A. Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J. Virol. 72:1998;1593-1599.
43. Qing K., Mah C., Hansen J., Zhou S., Dwarki V., Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Med. 5:1999;71-77.
44. Rendahl K. G., Leff S. E., Otten G. R., Spratt S. K., Bohl D., Roey M. V., Donahue B. A., Cohen L. K., Mandel R. J., Danos O., Snyder R. O. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nature Biotech. 16:1998;757-761.
45. Richardson W. D., Westphal H. Requirement for either early region 1a or early region 1b adenovirus gene products in the helper effect for adeno-associated virus. J. Virol. 51:1984;404-410.
46. Salvetti A., Oreve S., Chadeuf G., Favre D., Cherel Y., Champion-Arnaud P., David-Ameline J., Moullier P. Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9:1998;695-706.
47. Samulski R. J., Chang L.-S., Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61:1987;3096-3101.
48. r polypeptide facilitates timely cytoplasmic accumulation of adeno-associated virus mRNAs. J. Virol. 62:1988;206-210.
49. Samulski R. J., Chang L.-S., Shenk T. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63:1989;3822-3828.
50. Sandler A. B., Ketner G. Adenovirus early region 4 is essential for normal stability of late nuclear RNAs. J. Virol. 63:1989;624-630.
51. Scaria A., Curiel D. T., Kay M. A. Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. Gene Ther. 2:1995;295-298.
52. Shi Y., Seto E., Chang L.-S., Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 67:1991;377-388.
53. Snyder R. O., Miao C. H., Patijn G. A., Spratt S. K., Danos O., Nagy D., Gown A. M., Winther B., Meuse L., Cohen L. K., Thompson A. R., Kay M. A. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet. 16:1997;270-276.
54. Snyder R. O., Miao C., Meuse L., Tubb J., Donahue B. A., Lin H.-F., Stafford D. W., Patel S., Thompson A. R., Nichols T., Read M. S., Bellinger D. A., Brinkhous K. M., Kay M. A. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med. 5:1999;64-70.
55. Song S., Morgan M., Ellis T., Poirier A., Chestnut K., Wang J., Brantly M., Muzyczka N., Byrne B. J., Atkinson M., Flotte T. R. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA. 95:1998;14384-14388.
56. Summerford C., Samulski R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1998;1438-1445.
57. Summerford C., Bartlett J. S., Samulski R. J. αVβ5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nature Med. 5:1999;78-82.
58. Teramoto S., Bartlett J. S., McCarty D., Xiao X., Samulski R. J., Boucher R. C. Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: Comparison with adenovirus vectors. J. Virol. 72:1998;8904-8912.
59. Tratschin J. D., Tal J., Carter B. J. Negative and positive regulation in trans of gene expression from adeno-associated virus vectors in mammalian cells by a viral rep gene product. Mol. Cell. Biol. 6:1986;2884-2894.
60. Trempe J. P., Carter B. J. Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein. J. Virol. 62:1988;3356-3363.
61. Vincent K. A., Piraino S. T., Wadsworth S. C. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J. Virol. 71:1997;1897-1905.
62. Wang X.-S., Khuntirat B., Qing K., Ponnazhagan S., Kube D. M., Zhou S., Dwarki V. J., Srivastava A. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J. Virol. 72:1998;5472-5480.
63. Weger S., Wistuba A., Grimm D., Kleinschmidt J. A. Control of adeno-associated virus type 2 cap gene expression: Relative influence of helper virus, terminal repeats, and rep proteins. J. Virol. 71:1997;8437-8447.
64. 1 RNA. Virology. 160:1987;38-47.
65. Xiao X., McCown T. J., Li J., Breese G. R., Morrow A. L., Samulski R. J. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA (A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res. 756:1997;76-83.
66. Xiao X., Li J., Samulski R. J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:1998;2224-2232.
67. Xiao W., Berta S. C., Lu M. M., Moscioni A. D., Tazelaar J., Wilson J. M. Adeno-associated virus as a vector for liver-directed gene therapy. J. Virol. 72:1998;10222-10226.
68. Ye X., Rivera V. M., Zoltick P., Cerasoli F. Jr., Schnell M. A., Goa G., Hughes J. V., Gilman M., Wilson J. M. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 283:1999;88-91.
69. Zeitlin P. L., Lu L., Rhim J., Cutting G., Stetten G., Kieffer K. A., Craig R., Guggino W. B. A cystic fibrosis bronchial epithelial cell line: Immortalization by adeno-12-SV40 infection. Am. J. Respir. Cell Mol. Biol. 4:1991;313-319.
70. Zeitlin P. L., Chu S., Conrad C., McVeigh U., Ferguson K., Flotte T. R., Guggino W. B. Alveolar stem cell transduction by an adeno-associated viral vector. Gene Ther. 2:1995;623-631.
71. Zolotukhin S., Byrne B. J., Mason E., Zolotukhin I., Potter M., Chestnut K., Summerford C., Samulski R. J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:1999;973-985.